LYB NYSE
LyondellBasell Industries N.V.

What happened
+6.41% 2026-03-04

From 2026-03-04 session.

KeyBanc upgrade and Middle East supply shock thesis lift shares against flat sector

LyondellBasell Industries stock rose 6.4% following several developments. The company announced a quarterly dividend reduction to $0.69 per share from the prior $1.37, citing challenging market conditions and a need to preserve cash. Full year 2025 results showed a net loss of $738 million, though the company generated $2.3 billion in operating cash flow and returned $2 billion to shareholders.

Full analysis covers our editorial take, sources, and more.

Track LYB — big moves explained

What happened. Why it matters. 30 seconds.

LYB explained

What does LyondellBasell Industries N.V. do?

LyondellBasell is one of the world's largest producers of polypropylene and a major polyethylene manufacturer, supplying raw materials for packaging, automotive, and construction end markets. The Houston-based company is navigating a prolonged industry downturn — posting a $738 million net loss in 2025 and cutting its dividend by 50% — while pursuing European asset divestitures and an $800 million cash improvement plan. The current rally centers on whether Iran-related disruptions to Middle East chemical exports could finally break the global oversupply that has compressed its margins.

How does WTF Just Happened track LyondellBasell Industries N.V.?

We watch LYB for moves that stand out from normal trading -- the kind of day that makes you ask "WTF just happened?" When LyondellBasell Industries N.V. moves beyond its usual range, our AI digs through 15-20 news sources to piece together what drove it. No predictions, no trading advice -- just a clear explanation in about 30 seconds.

See what else moved today →

What a WTF analysis looks like

From a recent analysis

The gain is consistent with pre-earnings positioning ahead of a significant dual catalyst: the Q4 report after today's close and an in-person Investor Day tomorrow morning. the stock outperformed the healthcare sector (XLV +0.11%) by more than four percentage points and its MedTech peer average (+1.3%) by roughly three points, pointing to stock-specific activity rather than sector lift. The stock has traded near its 52-week low throughout February in a pattern of catalyst-free choppy declines, making today's earnings and Investor Day the first fundamental catalysts in weeks. Notably, Benzinga flagged that the stock's last earnings beat in Q3 was followed by a 9.7% drop the next day — a reminder that the post-report reaction may diverge sharply from pre-report positioning.